We are live on ! Find out more
TXMD icon

TherapeuticsMD
TXMD

Fund managers haven’t disclosed any holdings of TXMD yet.

TXMD Hedge Fund Activity: Q1 2026 in Review

49 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2026, worth a combined $7.92M — up 44% from $5.52M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TXMD positions and 3 closed out — a net gain of 7 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $945K. The largest seller was Susquehanna International Group, cutting an estimated $31.4K.

  • 49 institutional investors held TherapeuticsMD (TXMD) as of Q1 2026, up from 44 in Q4 2025.
  • Funds reported $7.92M of TherapeuticsMD stock for Q1 2026, up 44% quarter-over-quarter.
  • 10 funds opened new TherapeuticsMD positions in Q1 2026 and 3 closed out, a net change of +7 holders.
  • The largest TherapeuticsMD buyer in Q1 2026 was Squadron Capital Management, an estimated $945K added.
  • The largest TherapeuticsMD seller in Q1 2026 was Susquehanna International Group, an estimated $31.4K sold.

Based on aggregated 13F filings for Q1 2026.